An isolated human monoclonal antibody, or an antigen-binding portion thereof, selected from the group consisting of: (i) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:1; b) a heavy chain variable region CDR2 comprising SEQ ID NO:4; c) a heavy chain variable region CDR3 comprising SEQ ID NO:7; d) a light chain variable region CDR1 comprising SEQ ID NO:10; e) a light chain variable region CDR2 comprising SEQ ID NO:13; and f) a light chain variable region CDR3 comprising SEQ ID NO:16; (ii) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:2; b) a heavy chain variable region CDR2 comprising SEQ ID NO:5; c) a heavy chain variable region CDR3 comprising SEQ ID NO:8; d) a light chain variable region CDR1 comprising SEQ ID NO:11; e) a light chain variable region CDR2 comprising SEQ ID NO:14; and f) a light chain variable region CDR3 comprising SEQ ID NO:17; and (iii) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:3; b) a heavy chain variable region CDR2 comprising SEQ ID NO:6; c) a heavy chain variable region CDR3 comprising SEQ ID NO:9; d) a light chain variable region CDR1 comprising SEQ ID NO:12; e) a light chain variable region CDR2 comprising SEQ ID NO:15; and f) a light chain variable region CDR3 comprising SEQ ID NO:18; wherein the antibody, or an antigen-binding portion thereof, binds to Glypican-3. (i) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:1; b) a heavy chain variable region CDR2 comprising SEQ ID NO:4; c) a heavy chain variable region CDR3 comprising SEQ ID NO:7; d) a light chain variable region CDR1 comprising SEQ ID NO:10; e) a light chain variable region CDR2 comprising SEQ ID NO:13; and f) a light chain variable region CDR3 comprising SEQ ID NO:16; a) a heavy chain variable region CDR1 comprising SEQ ID NO:1; b) a heavy chain variable region CDR2 comprising SEQ ID NO:4; c) a heavy chain variable region CDR3 comprising SEQ ID NO:7; d) a light chain variable region CDR1 comprising SEQ ID NO:10; e) a light chain variable region CDR2 comprising SEQ ID NO:13; and f) a light chain variable region CDR3 comprising SEQ ID NO:16; (ii) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:2; b) a heavy chain variable region CDR2 comprising SEQ ID NO:5; c) a heavy chain variable region CDR3 comprising SEQ ID NO:8; d) a light chain variable region CDR1 comprising SEQ ID NO:11; e) a light chain variable region CDR2 comprising SEQ ID NO:14; and f) a light chain variable region CDR3 comprising SEQ ID NO:17; and a) a heavy chain variable region CDR1 comprising SEQ ID NO:2; b) a heavy chain variable region CDR2 comprising SEQ ID NO:5; c) a heavy chain variable region CDR3 comprising SEQ ID NO:8; d) a light chain variable region CDR1 comprising SEQ ID NO:11; e) a light chain variable region CDR2 comprising SEQ ID NO:14; and f) a light chain variable region CDR3 comprising SEQ ID NO:17; and (iii) an antibody, or an antigen binding portion thereof, comprising: a) a heavy chain variable region CDR1 comprising SEQ ID NO:3; b) a heavy chain variable region CDR2 comprising SEQ ID NO:6; c) a heavy chain variable region CDR3 comprising SEQ ID NO:9; d) a light chain variable region CDR1 comprising SEQ ID NO:12; e) a light chain variable region CDR2 comprising SEQ ID NO:15; and f) a light chain variable region CDR3 comprising SEQ ID NO:18; wherein the antibody, or an antigen-binding portion thereof, binds to Glypican-3. a) a heavy chain variable region CDR1 comprising SEQ ID NO:3; b) a heavy chain variable region CDR2 comprising SEQ ID NO:6; c) a heavy chain variable region CDR3 comprising SEQ ID NO:9; d) a light chain variable region CDR1 comprising SEQ ID NO:12; e) a light chain variable region CDR2 comprising SEQ ID NO:15; and f) a light chain variable region CDR3 comprising SEQ ID NO:18; wherein the antibody, or an antigen-binding portion thereof, binds to Glypican-3.